Aurinia Pharmaceuticals Inc (AUPH) is a Healthcare · Biotechnology company listed on NASDAQ. Price $16.95 (-0.06%), Market cap $2.01B, P/E ratio 7.22, 52-week low–high $7.47 ~ $16.42.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Financial statements, price targets, institutional (13F) holdings and related news for Aurinia Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Aurinia Pharmaceuticals Inc trades at $16.95 (-0.06%). Real-time quotes and charts are available on BlackAll Trade.
Aurinia Pharmaceuticals Inc has a market cap of about $2.01B. Its P/E ratio is 7.22.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The c